CN101057852A - Compound enteritis capsule - Google Patents
Compound enteritis capsule Download PDFInfo
- Publication number
- CN101057852A CN101057852A CNA2007100543173A CN200710054317A CN101057852A CN 101057852 A CN101057852 A CN 101057852A CN A2007100543173 A CNA2007100543173 A CN A2007100543173A CN 200710054317 A CN200710054317 A CN 200710054317A CN 101057852 A CN101057852 A CN 101057852A
- Authority
- CN
- China
- Prior art keywords
- enteritis
- compound
- intestine
- capsule
- furazolidone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention provides a compound enteritis capsule. It is characterized by simple treatment, convenient usage and functions of treating bacillary dysentery, acute and chronic enteritis. It makes use of the anti-biotic effect for bacillus coli and Bacillus dysenteriae of furazolidone, acts on intestine smooth muscle by using chlorhydric acid diphenoxylate, gets rid of crawl reflection of partial mucosa to reduce crawl by inhibiting intestine mucosa receptor, and increases intestine wall stage contraction and promotes water back-absorption in the intestine. The atropine sulfate can relieve intestine smooth muscle spasm and inhibit glandular secretion. The capsule comprises five chemical medicine, it can shorten the treating period for bacillary dysentery and acute enteritis, increase cure rate for various chronic colitis, and reduce pain for patient during injection, intravenous drip, bowel lavage and taking traditional medicine.
Description
Affiliated technical field
The present invention is used for the treatment of that bacillary dysentery, acute enteritis, various chronic colitis, Anaphylaxis enteritis, crow are rushed down, agnogenio diarrheal chemicals compound formulation.
Background technology
At present the scheme of treatment bacillary dysentery, various acute chronic enteritis is oral, intramuscular injection, quiet chemicals, and coloclysis, preparation takes traditional Chinese medicine.Effect is slow, and curative effect can not be affirmed, infectious intestinal disease can not in time be controlled, and sickness rate significantly increases.To the chronic colitis weak curative effect, making the course of disease reach several years to many decades can not cure.Become a great problem that perplexs medical circle for a long time.
Summary of the invention
Slow to the infectious intestinal disease curative effect at present in order to solve, treatment cycle is long, various chronic colitiss, crow are rushed down the problem that is difficult to effect a radical cure, and the oral administered compound capsule for treating enteritis can in time control infectious intestinal disease, improve cure rate to chronic enteritis, alleviate in the therapeutic process because of intramuscular injection, quiet, coloclysis, the misery that takes traditional Chinese medicine and bring to the patient.
The technical solution adopted for the present invention to solve the technical problems is: with oxytetracycline, the furazolidone antibacterial action to escherichia coli and dysentery bacterium; Cooperate prednisone can improve antiinflammatory action, and reduce the inflammatory exudation of intestinal wall, the antagonism anaphylactogen; Directly act on intestinal smooth muscle with diphenoxylate hydrochloride, by inhibition intestinal mucosa sensor, eliminate the wriggling reflection of local mucosa and weaken wriggling, can increase the interim contraction of intestinal wall simultaneously, the resorption of promotion enteral moisture is received.Can remove the spasm of intestinal smooth muscle with atropine sulfate, suppress the effect of glandular secretion.Solved at present bacillary dysentery, problem that the acute enteritis treatment cycle is long, not obvious to various chronic colitis curative effects, that cure rate is low with the synthetic compound enteritis capsule of these several chemicalses.
The invention has the beneficial effects as follows: when treating acute enteritis, bacillary dysentery, also can improve cure rate various chronic colitiss.Adopt the chemicals compound formulation, cost is low, processing technology is simple.More than 98%, cure rate is more than 95% to acute enteritis, bacillary dysentery effective percentage.More than 90%, cure rate is more than 80% to the chronic colitis effective percentage.
The example explanation
The present invention is further described with prescription below in conjunction with embodiment.
Example 1: the Wang Dianying in Wang Gou village, the smooth town of Yuzhou City, Henan Province letter suffers from acute enteritis, twice back recovery from illness of oral administered compound capsule for treating enteritis.
Example 2: year surplus Fang Gang township, Yuzhou City, the Henan Province Liu Gang village Liu Fu gold trouble chronic colitis ten, the back recovery from illness of one week of oral administered compound capsule for treating enteritis.
Concrete prescription is: per 1000 compound enteritis capsules contain
25 milligrams of oxytetracycline 250 gram furazolidone 50 gram prednisones 5 gram diphenoxylate hydrochlorides 2.5 gram atropine sulfates.
Claims (2)
1 one kinds of compound enteritis capsule preparations are according to oxytetracycline, the furazolidone antibacterial action to escherichia coli and dysentery bacterium; Cooperate prednisone can improve antiinflammatory action, the antagonism anaphylactogen; Diphenoxylate hydrochloride can reduce enterokinesia, increases the interim contraction of intestinal wall, promotes the resorption of enteral moisture to receive; Can remove the spasm of intestinal smooth muscle with atropine sulfate, suppress the effect of glandular secretion, it is characterized in that by oxytetracycline, furazolidone, prednisone, diphenoxylate hydrochloride, the synthetic in proportion compound capsule of five kinds of chemicalses of atropine sulfate.
2 compound enteritis capsules according to claim 1 is characterized in that: by oxytetracycline, furazolidone, prednisone, diphenoxylate hydrochloride, five kinds of chemicalses of atropine sulfate (per 1000 compound enteritis capsules contain 25 milligrams of oxytetracycline 250 grams, furazolidone 50 grams, prednisone 5 grams, diphenoxylate hydrochloride 2.5 grams, atropine sulfate) synthetic compound capsule in proportion.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007100543173A CN101057852A (en) | 2007-04-28 | 2007-04-28 | Compound enteritis capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007100543173A CN101057852A (en) | 2007-04-28 | 2007-04-28 | Compound enteritis capsule |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101057852A true CN101057852A (en) | 2007-10-24 |
Family
ID=38864256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007100543173A Pending CN101057852A (en) | 2007-04-28 | 2007-04-28 | Compound enteritis capsule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101057852A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108904457A (en) * | 2018-08-07 | 2018-11-30 | 河北赛克药业有限公司 | R-1132 and preparation method thereof |
| CN111617107A (en) * | 2020-04-10 | 2020-09-04 | 王全栋 | Pharmaceutical composition for treating colitis |
-
2007
- 2007-04-28 CN CNA2007100543173A patent/CN101057852A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108904457A (en) * | 2018-08-07 | 2018-11-30 | 河北赛克药业有限公司 | R-1132 and preparation method thereof |
| CN111617107A (en) * | 2020-04-10 | 2020-09-04 | 王全栋 | Pharmaceutical composition for treating colitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101152253A (en) | Traditional Chinese medicine for treating various rhinitis | |
| NZ600803A (en) | Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitis | |
| CN101057852A (en) | Compound enteritis capsule | |
| CN101612280A (en) | A kind of unguentum that is used for the treatment of rhinitis and nasosinusitis | |
| CN103656025B (en) | A kind of medical liquor for treating injury | |
| RU2008134118A (en) | Intraventricular protein delivery in amyotrophic lateral sclerosis | |
| CN101953496A (en) | Lithiasis recovery drinks | |
| CN1600333A (en) | Painkiller | |
| CN1294930C (en) | Medication for treating cough caused by inflammation of upper respiratory tract | |
| CN1235608C (en) | Medicine for curing prostatosis and its preparation method | |
| CN101152328A (en) | Traditional Chinese medicine for treating rhinostegnosis of chronic rhinitis | |
| CN101632762A (en) | Traditional Chinese medicine ointment for treating child aphtha | |
| CN101167968A (en) | Traditional Chinese medicine for treating infantile paralytic sequelae | |
| CN1125110A (en) | drug for curing gastropathy | |
| CN1043958C (en) | Traditional Chinese medicinal liquor for treatment of stomach trouble | |
| CN103720648B (en) | Aqueous injection of a kind of hydrochloric mepivacaine and preparation method thereof | |
| CN101199620B (en) | Oral administration medicated liquor for treating sprain | |
| CN101152225A (en) | Traditional Chinese medicine for treating uncinariasis | |
| CN101057891A (en) | Compound capsule for treating stomachache | |
| CN1861083B (en) | Compound medicine for treating migraine headache | |
| CN1861088A (en) | Nasal drip liquor for treating rhinitis and nasosinusitis | |
| CN1280839A (en) | Chinese-medicinal nose drops for treating acute or chronic rhinitis and its preparing process | |
| CN107753825A (en) | A kind of Chinese medicine composition for treating pathogenic cold stomach invading type stomach trouble | |
| CN1520845A (en) | Nasal administration drug for cold | |
| CN1058407C (en) | Medicament for treating gastropathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |